Carlo Torti

Summary

Affiliation: University of Brescia
Country: Italy

Publications

  1. doi request reprint Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy
    C Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Clin Microbiol Infect 18:449-58. 2012
  2. doi request reprint High prevalence of radiological vertebral fractures in HIV-infected males
    Carlo Torti
    Institute of Infectious and Tropical Diseases, School of Medicine, University of Brescia, P le Spedali Civili, 1, 25123 Brescia, Italy
    Endocrine 41:512-7. 2012
  3. pmc Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, P le Spedali Civili, 125123 Brescia, Italy
    BMC Med 9:138. 2011
  4. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
  5. ncbi request reprint Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients
    Carlo Torti
    School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drug Saf 30:1161-9. 2007
  6. ncbi request reprint Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors
    Giuseppe Lapadula
    Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
    Antivir Ther 13:601-5. 2008
  7. doi request reprint Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection
    Monia Mendeni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Clin Infect Dis 52:1164-73. 2011
  8. ncbi request reprint Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
    J Acquir Immune Defic Syndr 41:180-5. 2006
  9. ncbi request reprint Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    J Clin Virol 35:414-9. 2006
  10. ncbi request reprint Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008

Detail Information

Publications50

  1. doi request reprint Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy
    C Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Clin Microbiol Infect 18:449-58. 2012
    ..However, owing to the small sample size, further studies are needed to confirm these results in relation to clinical endpoints...
  2. doi request reprint High prevalence of radiological vertebral fractures in HIV-infected males
    Carlo Torti
    Institute of Infectious and Tropical Diseases, School of Medicine, University of Brescia, P le Spedali Civili, 1, 25123 Brescia, Italy
    Endocrine 41:512-7. 2012
    ..Furthermore, proactive diagnosis of vertebral fragility fractures is particularly relevant in patients who are overweight or suffer from diabetes...
  3. pmc Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, P le Spedali Civili, 125123 Brescia, Italy
    BMC Med 9:138. 2011
    ..Moreover, it is important to understand whether new biomarkers or neuroimaging tools can help to identify better the most at risk population. Please see related article: http://www.biomedcentral.com/1471-2334/11/356...
  4. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
    ..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
  5. ncbi request reprint Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients
    Carlo Torti
    School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drug Saf 30:1161-9. 2007
    ..Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV)...
  6. ncbi request reprint Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors
    Giuseppe Lapadula
    Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
    Antivir Ther 13:601-5. 2008
    ..Prevalence and factors associated with etravirine (EW) resistance mutations among patients failing on first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) merit investigation...
  7. doi request reprint Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection
    Monia Mendeni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Clin Infect Dis 52:1164-73. 2011
    ..There is lack of data on the incidence of liver fibrosis (LF) progression in patients with human immunodeficiency virus (HIV) monoinfection and risk factors for LF...
  8. ncbi request reprint Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
    J Acquir Immune Defic Syndr 41:180-5. 2006
    ..The independent role of hepatitis C virus (HCV) genotype 3 in liver transaminase elevation following highly active antiretroviral regimens is still controversial...
  9. ncbi request reprint Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    J Clin Virol 35:414-9. 2006
    ..To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure...
  10. ncbi request reprint Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008
    ..The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations...
  11. ncbi request reprint CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
    Carlo Torti
    Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    J Antimicrob Chemother 59:1141-7. 2007
    ..We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination...
  12. ncbi request reprint Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Patient Care STDS 21:92-9. 2007
    ..4; 95% CI 0.2-0.8; p = 0.014) were both negative independent predictors of sustained virologic response, while the use of boosted protease inhibitor-containing regimens resulted to be protective (OR: 2.4; 95% CI 1.1-5.3; p = 0.032)...
  13. ncbi request reprint Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3
    Giuseppe Lapadula
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    Antivir Ther 12:941-7. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events (ADE) or death among patients who started HAART with CD4+ T-cell counts > or =200 cells/mm3 have rarely been assessed simultaneously...
  14. ncbi request reprint Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Curr HIV Res 6:43-8. 2008
    ..Further studies are needed to compare pVL decay between antiretroviral regimens and assess whether proviral HIV-DNA load is a surrogate marker of treatment effectiveness...
  15. ncbi request reprint Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    Int J Antimicrob Agents 29:185-90. 2007
    ..The presence of HCV and/or HBV co-infections correlated with higher plasma drug concentrations, although it did not appear to influence hepatotoxicity risk...
  16. ncbi request reprint Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy
    Giuseppe Lapadula
    Istituto per le Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
    Antivir Ther 11:521-7. 2006
    ..The independent role of HCV genotype 3 (HCV-3) in dyslipidaemia following highly active antiretroviral therapy (HAART) is still unexplored...
  17. doi request reprint Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis
    Giuseppe Lapadula
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Med Virol 80:747-53. 2008
    ..38; 95% CI:0.17-0.86; P = 0.020). Prevalence of primary resistance mutations suggests that genotypic resistance testing should be performed before starting treatment in naïve patients in Italy, particularly when NNRTI are prescribed...
  18. pmc Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    BMC Infect Dis 5:58. 2005
    ....
  19. doi request reprint Screening and Management of HIV-2-Infected Individuals in Northern Italy
    Silvia Costarelli
    Institute of Infectious and Tropical Diseases, University of Brescia, Brecia, Italy
    AIDS Patient Care STDS 22:489-94. 2008
    ..Accurate screening programs and integration of virological tools must be implemented urgently, given the high prevalence of HIV-2, particularly in immigrant patients...
  20. ncbi request reprint Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART
    Maria Cristina Uccelli
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Ann Nutr Metab 50:247-52. 2006
    ..Homocysteinemia (Hcy) increase and risk factors in HIV-positive patients are not clear yet...
  21. ncbi request reprint Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    J Antimicrob Chemother 56:190-5. 2005
    ....
  22. ncbi request reprint Predictors of AIDS-defining events among advanced naïve patients after HAART
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 8:112-20. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously...
  23. ncbi request reprint A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regi
    Carlo Torti
    Institute for Infectious and Tropical Diseases, Brescia, Italy
    Clin Infect Dis 40:1828-36. 2005
    ....
  24. ncbi request reprint Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 10:505-13. 2005
    ....
  25. ncbi request reprint Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretro
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    J Med Virol 74:29-33. 2004
    ....
  26. doi request reprint A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz
    Laura Albini
    Department of Materno Infantile e Tecnologie Biomediche, Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Acquir Immune Defic Syndr 59:18-30. 2012
    ..There is lack of data on GFR estimated by these methods in patients on highly active antiretroviral therapy...
  27. ncbi request reprint Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target?
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Intervirology 47:350-4. 2004
    ....
  28. ncbi request reprint Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART)
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Viral Immunol 17:279-86. 2004
    ....
  29. ncbi request reprint Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Med Sci Monit 9:CS16-9. 2003
    ..Resistance testing on the proviral genome has been suggested in order to detect the presence of archived resistance mutations and to guide drug prescription...
  30. pmc Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
    Emanuele Focà
    Infectious Diseases Department, University of Brescia, Brescia, Italy
    BMC Infect Dis 12:38. 2012
    ..Lastly, the effect of tenofovir on 1,25-(OH)₂ vitamin D is uncertain...
  31. ncbi request reprint Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    Health Policy 65:261-7. 2003
    ..To assess the impact of highly active antiretroviral therapy (HAART) on health resource utilisation (HRU) and to estimate associated direct costs in a population based setting...
  32. ncbi request reprint For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features
    Manuela Fogli
    Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Piazzale Spedali Civili, Brescia, Italy
    New Microbiol 37:75-80. 2014
    ..Results obtained suggest that a combination of these parameters could be an adequate surrogate marker of immunological competence. This will be helpful in deciding when to start HAART. ..
  33. ncbi request reprint Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop
    Giampiero Carosi
    Department of Infectious Disease, University of Brescia, Brescia, Italy
    AIDS Rev 7:161-7. 2005
    ....
  34. ncbi request reprint Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy
    Eugenia Quiros-Roldan
    Infectious Diseases Clinic, University of Brescia, Italy
    J Clin Lab Anal 16:76-8. 2002
    ..A slow decline in the detectability of mutations encoding NNRTI resistance was found...
  35. doi request reprint Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use
    Emanuele Focà
    Department for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Drugs 72:1161-73. 2012
    ..Moreover, therapeutic drug monitoring could be useful in specific circumstances (such as in patients with liver impairment or in case of potential drug-drug interactions)...
  36. ncbi request reprint Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy
    Emanuele Focà
    Infectious Diseases Department, University of Brescia, Brescia, Italy
    New Microbiol 35:227-31. 2012
    ..At the same time, HAART proved effective in reducing HCMV DNAemia without the need for a specific therapy...
  37. ncbi request reprint Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
    J Infect Dis 188:194-201. 2003
    ..52-5.52; P=.001; RetroGram: OR, 2.34; 95% CI, 1.21-4.55; P=.012), whereas, in contrast to real or virtual phenotype, interpretations according to biological cut-offs were not (OR, 1.91; 95% CI, 0.77-4.76; P=.162)...
  38. pmc Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy)
    Ilaria Izzo
    Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy
    BMC Public Health 11:124. 2011
    ..Therefore, we examined pregnant women by regional provenance and measured variables that could be associated with detectable HIV RNA at delivery...
  39. ncbi request reprint Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 9:139-42. 2004
  40. pmc Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance
    Manuela Fogli
    Section of Microbiology, Department of Experimental and Applied Medicine, University of Brescia, Spedali Civili Square, 25123 Brescia, Italy
    Clin Dev Immunol 2012:829584. 2012
    ..These results provide new insights on B cell in HIV-1 infection and show that development of B cell abnormalities precedes CD4⁺ T cell decline...
  41. pmc Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
    Davide Motta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Res Ther 9:18. 2012
    ..abstract:..
  42. ncbi request reprint SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression
    Eugenia Quiros-Roldan
    Department of Infectious and Tropical Diseases, Spedali Civili of Brescia, 25123, Italy
    AIDS Res Hum Retroviruses 19:1079-82. 2003
    ..At multivariate analysis, SENV infection did not appear to have any negative impact on survival, while a possible protective effect needs further investigation...
  43. pmc Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients
    Eugenia Quiros-Roldan
    Laboratory of Biotechnology, Diagnostics Department, Spedali Civili of Brescia, Brescia, Italy
    J Transl Med 10:94. 2012
    ....
  44. ncbi request reprint Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study
    Andrea Patroni
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 3:451-61. 2002
    ..Lipid disturbances have also been associated with hepatitis C virus (HCV) chronic infection in HIV-uninfected participants. HAART-induced lipid abnormalities may then have peculiar features in HIV-HCV co-infected individuals...
  45. pmc Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report
    Giuseppe Lapadula
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Med Case Reports 1:19. 2007
    ..Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage...
  46. ncbi request reprint A king in the CASTLE? Optimum initial HIV protease inhibitor
    Carlo Torti
    Institute of Infectious and Tropical Diseases, University of Brescia, I 25123 Brescia, Italy
    Lancet 372:604-6. 2008
  47. ncbi request reprint Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules
    Daria Gotti
    Institute for Infectious and Tropical Disease, University of Brescia, Brescia, Italy
    Curr HIV Res 9:61-9. 2011
    ....
  48. ncbi request reprint [The novel non-A, non-E hepatitis viruses and their pathogenic effect]
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, Spedali Civili, Brescia, Italy
    Med Clin (Barc) 122:552-4. 2004
    ..Only a careful evaluation of the data and the scientific concordance of all the evidence will resolve the question of whether they are only commensal viruses or pose a real pathogenic potential...
  49. ncbi request reprint [New strategies and new drugs in the salvage therapy for HIV infection]
    Eugenia Quiros-Roldan
    Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    Med Clin (Barc) 118:222-4. 2002